Prognostic Significance of TP53 Mutations and Single Nucleotide Polymorphisms in Acute Myeloid Leukemia: A case Series and Literature Review |
Zeichner, Simon Blechman
(Department of Internal Medicine, Mount Sinai Medical Center, University of Chicago)
Alghamdi, Sarah (Department of Pathology, Mount Sinai Medical Center, University of Chicago) Elhammady, Gina (Department of Molecular Genetic Pathology, University of Chicago) Poppiti, Robert John (Department of Pathology, Mount Sinai Medical Center, University of Chicago) Castellano-Sanchez, Amilcar (Department of Pathology, Mount Sinai Medical Center, University of Chicago) |
1 | Melo MB, Ahmad NN, Lima CS, et al (2002). Mutations in the p53 gene in acute myeloid leukemia patients correlate with poor prognosis. Hematology, 7, 13-9. DOI |
2 | Dunna NR, Vure S, Sailaja K, et al (2012). TP53 codon 72 polymorphism and risk of acute leukemia. Asian Pac J Cancer Prev, 13, 347-50. DOI |
3 | Cox DR (1972). Regression models and life tables. J R Stat Soc, 34, 187-202. |
4 | Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM(2012). Acute leukemia incidence and patient survivalamong children and adults in the United States, 2001-2007. Blood, 119, 34. DOI |
5 | Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M(2003). The codon 72 polymorphic variants of p53 havemarkedly different apoptotic potential. Nat Genet, 33,357-65. DOI ScienceOn |
6 | Ellis NA, Huo D, Yildiz O, et al (2008). MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acutemyeloid leukemia susceptibility. Blood, 112, 741-9. DOI |
7 | Estey EH (2001). Therapeutic options for acute myelogenous leukemia. Cancer, 92, 1059. DOI |
8 | Green CL, Evans CM, Hills RK, et al (2010). The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITDstatus. Blood, 116, 2779. DOI |
9 | Grimwade D, Hills RK, Moorman AV, et al (2010). Refinement of cytogenetic classification in acute myeloid leukemia:determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adultpatients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354. DOI |
10 | Grimwade D, Hills RK, Moorman AV, et al (2010). Refinement of cytogenetic classification in acute myeloid leukemia:determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adultpatients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354. DOI |
11 | Anensen N, Hjelle SM, Van Belle W, et al (2012). Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene, 31, 1533-45. DOI ScienceOn |
12 | Appelbaum FR, Gundacker H, Head DR, et al (2006). Age and acute myeloid leukemia. Blood, 107, 3481. DOI ScienceOn |
13 | Yamamoto JF, Goodman MT (2008). Patterns of leukemiaincidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control, 19, 379. DOI |
14 | Zeichner SB (2012). Acute myeloid leukemia, genetics, and risk stratification: data overload or readyfor a breakthrough? J Am Osteopath Assoc, 112, 463-5. |
15 | Zhuo W, Zhang L, Ling J, Zhu B, Chen Z (2012). MDM2 SNP309variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymphoma, 53, 2245-52. DOI |
16 | Bennett JM, Catovsky D, Daniel MT, et al (1985). Proposed revised criteria for the classification of acute myeloidleukemia. A report of the French-American-BritishCooperative Group. Ann Intern Med, 103, 620. DOI ScienceOn |
17 | Breems DA, Van Putten WL, De Greef GE, et al (2008). Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol, 26, 4791-7. DOI |
18 | Cavalcanti GB Jr, Scheiner MA, Simoes Magluta EP, et al (2010).p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome. Cytometry B Clin Cytom,78, 253-9. |
19 | Christiansen DH, Andersen MK (2001), Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloidleukemia after exposure to alkylating agents and significantlyassociated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol, 1, 19, 1405-13. DOI |
20 | Wheatley K, Burnett AK, Goldstone AH, et al (1999). Asimple, robust, validated and highly predictive index forthe determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and ChildhoodLeukaemia Working Parties. Br J Haematol, 107, 69. DOI ScienceOn |
21 | Stojnev S, Golubovic M, Babovic P (2010). TP53 gene mutationsfrom guardian of the genome to oncogene. Acta Medica Medianae, 49, 59-63. |
22 | Wattel E, Preudhomme C, Hecquet B, et al (1994). p53 mutationsare associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148-57. |
23 | Suciu GP, Lemeshow S, Moeschberger M (2004), Statistical Test of Equality of Survival Curves: Reconsidering the Options, Handbook of Statistics, Vol.23, Chapter 13. Eds. N.Balakrishnan and C.R.Rao, Elsevier Science B.V. p251-262, ISSN:0169-7161. |
24 | Stirewalt DL, Kopecky KJ, Meshinchi S, et al (2001). FLT3, RAS, and TP53 mutations in elderly patients with acutemyeloid leukemia. Blood, 97, 3589-95. DOI ScienceOn |
25 | Stone RM (2002). The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin, 52, 363. DOI |
26 | Summers K, Stevens J, Kakkas I, et al (2007). Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia, 21, 550. DOI |
27 | Tavor S, Rothman R, Golan T, et al (2011). Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia. Leuk Lymphoma,52, 642-7. DOI |
28 | Thomas M, Kalita A, Labrecque S, et al (1999). Twopolymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100. DOI |
29 | Vardiman JW, Thiele J, Arber DA, et al (2009). The 2008 revisionof the World Health Organization (WHO) classificationof myeloid neoplasms and acute leukemia: rationale andimportant changes. Blood, 114, 937. DOI ScienceOn |
30 | Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53network. Nature, 408, 307-10. DOI ScienceOn |
31 | Sant M, Allemani C, Tereanu C, et al (2010). Incidence ofhematologic malignancies in Europe by morphologicsubtype: results of the HAEMACARE project. Blood, 116,3724. DOI ScienceOn |
32 | Pim D, Banks L (2004). p53 polymorphic variants at codon72 exert different effects on cell cycle progression. Int J Cancer, 108, 196-9. DOI ScienceOn |
33 | Rucker FG, Russ AC, Cocciardi S, et al (2013). Altered miRNAand gene expression in acute myeloid leukemia with complexkaryotype identify networks of prognostic relevance.Leukemia, 27, 353-61. DOI |
34 | Rucker FG, Schlenk RF, Bullinger L, et al (2012). TP53 alterations in acute myeloid leukemia with complexkaryotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 119,2114-21. DOI |
35 | Seifert H, Mohr B, Thiede C, et al (2009). The prognostic impactof 17p (p53) deletion in 2272 adults with acute myeloidleukemia. Leukemia, 23, 656-63. DOI |
36 | Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013.CA Cancer J Clin, 63, 11. DOI ScienceOn |
37 | Sigal A, Rotter V (2000). Oncogenic mutations of the p53 tumorsuppressor: the demons of the guardian of the genome. |
38 | Cancer Res, 60, 6788-93.Smith A, Howell D, Patmore R, Jack A, Roman E (2011). Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy ResearchNetwork. Br J Cancer, 105, 1684. DOI |
39 | Smith SM, Le Beau MM, Huo D, et al (2003). Clinicalcytogenetic associations in 306 patients with therapy-relatedmyelodysplasia and myeloid leukemia: the University ofChicago series. Blood, 102, 43-52. DOI ScienceOn |
40 | Nakano Y, Naoe T, Kiyoi H, et al (2000). Prognostic value of p53gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol, 65, 23-31. DOI |
41 | Milosevic JD, Puda A, Malcovati L, et al (2012). Clinicalsignificance of genetic aberrations in secondary acutemyeloid leukemia. Am J Hematol, 87, 1010-6. DOI |
42 | Mrozek K, Marcucci G, Nicolet D, et al (2012). Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations inadults with acute myeloid leukemia. J Clin Oncol, 30, 4515. DOI |
43 | Padua RA, Guinn BA, Al-Sabah AI, et al (1998). RAS, FMS andp53 mutations and poor clinical outcome in myelodysplasias:a 10-year follow-up. Leukemia. 12(6):887-92. DOI ScienceOn |
44 | Pardee TS, Zuber J, Lowe SW (2011). Flt3-ITD alterschemotherapy response in vitro and in vivo in a p53dependent manner. Exp Hematol, 39, 473-85. DOI |
45 | Paschka P, Schlenk RF, Gaidzik VI, et al (2010). IDH1 and IDH2mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutationwithout FLT3 internal tandem duplication. J Clin Oncol,28, 3636. |
46 | Patel MI, Ma Y, Mitchell BS, Rhoads KF (2013). Age and Genetics: How Do Prognostic Factors at Diagnosis Explain Disparities in Acute Myeloid Leukemia? Am J Clin Oncol. [Epub ahead of print]. |
47 | Patel MI, Ma Y, Mitchell BS, Rhoads KF (2012). Understandingdisparities in leukemia: a national study. Cancer Causes Control, 23, 1831-7. DOI |
48 | Pietsch EC, Humbey O, Murphy ME (2006). Polymorphisms inthe p53 pathway. Oncogene, 25, 1602-11. DOI ScienceOn |
49 | Grimwade D, Walker H, Oliver F, et al (1998). The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322. |
50 | Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, et al(2012). Myeloid neoplasms with isolated isochromosome17q represent a clinicopathologic entity associated withmyelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer,118, 2879-88. DOI |
51 | Harutyunyan A, Klampfl T, Cazzola M, Kralovics R (2011).p53 lesions in leukemic transformation. N Engl J Med,364, 488-90. DOI |
52 | Jadersten M, Saft L, Smith A, et al (2011). TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predictdisease progression. J Clin Oncol, 29, 1971-9. DOI |
53 | Kaplan EL, Meier P (1958). Nonparametric estimation fromincomplete observations. Am Stat Assoc J, 53, 457-81. DOI ScienceOn |
54 | Koushik A, Tranah GJ, Ma J, et al (2006). p53 Arg72Propolymorphism and risk of colorectal adenoma and cancer. Int J Cancer, 119, 1863-8. DOI ScienceOn |
55 | Krypuy M, Ahmed AA, Etemadmoghadam D, et al (2007). Highresolution melting for mutation scanning of TP53 exons 5-8. BMC cancer, 7, 168. DOI |
56 | Lehmann S, Bykov VJ, Ali D, et al (2012). Targeting p53 in vivo:a first-in-human study with p53-targeting compound APR246in refractory hematologic malignancies and prostate cancer. J Clin Oncol, 30, 3633-9. DOI |
57 | Matakidou A, Eisen T, Houlston RS (2003). TP53 polymorphismsand lung cancer risk: a systematic review and meta-analysis.Mutagenesis, 18, 377-85. DOI |
58 | Nahi H, Lehmann S, Bengtzen S, et al (2008). Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma,49, 508-16. DOI |
59 | Valcarcel D, Adema V, Sole F, et al (2013). Complex, notmonosomal, karyotype is the cytogenetic marker ofpoorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol, 31, 916-22. DOI |